David Roman Managing Director at Goldman Sachs Thank you
Clinical studies have demonstrated that, when combined with a reduced-calorie diet and increased physical activity, semaglutide can lead to substantial and sustained weight loss
Over the past decades, several randomized clinical trials (RCTs) have shown that GLP-1 RAs improve cardiovascular outcomes in patients with type 2 DM (T2DM) who have established CVDs or are at risk, as well as in individuals with CKD [16,17,18,19]
Studies have also explored its influence on neurological pathways, trust behaviors, and hormonal modulation
These are compounded medications, not brand-name
January to May 2026 (In Progress): Remaining TRIUMPH Phase 3 trials (1, 2, and 3) are being completed